Loading...

RAPT RAPT THERAPEUTICS INC Operational Disruptions 8-K Filing

RPT

RPT

RAPT THERAPEUTICS INC

(RAPT)

2023 8-K

Show Summary

Show Summary

- Delisting due to Non-Com...

Financial Statements

Financial Results

Investor Presentation

License Agreement

License Agreement

Stock Option Repricing

Financial Results

Earnings Reports

Workforce Reduction

Annual Meeting of Stockholders

Financial Results Announcement

Financial Results Announcement

FDA Clinical Hold

FDA Clinical Hold on Clinic...

Financial Results Announcement

Clinical Data Announcement

Sales Agreement

Earnings Reports

Annual Meeting of Stockholders

Financial Results Announcement

Financial Results Announcement

Filing of Investor Presenta...

External Links:

RAPT Therapeutics announced positive clinical data from its Phase 2 trial of FLX475 in patients with advanced non-small cell lung cancer (NSCLC) who had no prior checkpoint inhibitor therapy, showing a 40% confirmed objective response rate (ORR) in P

AI Assistant

RAPT THERAPEUTICS INC

2023

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.